Cytokinetics CEO Robert Blum: An Interview With “The Pink Sheet” DAILY (Part 2 Of 2)
This article was originally published in The Pink Sheet Daily
In the second part of the interview at the BIO Investor forum, CEO Robert Blum discusses Cytokinetics’ deal with Amgen and long-range commercialization goals.
You may also be interested in...
Chief exec sits down with “The Pink Sheet” DAILY at BIO Investor Forum to discuss lead candidates in oncology and heart failure, and partnering with big pharma.
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.
US vaccination campaign will pick up speed now that access is broadening, leaders from Operation Warp Speed, Pfizer, Moderna, McKesson and CVS Health say at a J.P. Morgan panel discussion.